Company intelligence / Profile preview

ECI Therapeutics

Garden City, New York, United Statesecitherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

ECI Therapeutics is developing a proprietary platform that combines platelet-rich plasma-derived growth factors with chitosan or hyaluronic acid for use in ophthalmic, wound, and burn care. The company’s lead programs target rare ophthalmic diseases such as neurotrophic keratopathy and common conditions like dry eye disease. No clinical trial results have been published yet; products are still under development.[1][2][4]

Therapeutic areas: Rare DiseasesCardiovascularOphthalmologyDermatology
Modalities: Plasma-derived growth factors (from human platelet-rich plasma)Chitosan-based excipientsHyaluronic acid-based excipients[1][2][5][6]
Industry: Biotech

Drug pipeline

3 assets

ECI-103

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ECI Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECI Therapeutics.

Explore the full profile